Oncology CRO: A Practical RFP Guide for Sponsors and Biotech Teams
What You’ll Learn in This Article
Table of Contents
- Key Challenges in Oncology Trials and What to Expect from Your Oncology CRO
- Oncology CRO Evaluation Criteria Sponsors Should Prioritizeto
- How to Choose the Right Oncology CRO
- Actionable RFP Questions for Choosing the Right Oncology CRO
- Common Pitfalls in Selecting an Oncology CRO (and How to Avoid Them)
- Choosing the Right Oncology CRO: What Really Matters
Selecting an oncology CRO is no longer just a vendor procurement exercise. In complex oncology trials, CRO selection directly affects enrollment timelines, protocol execution, regulatory readiness, and operational risk.
For sponsors and biotech teams, the challenge is not simply finding a CRO with oncology experience, but evaluating whether that partner can execute effectively under real-world trial conditions.
This guide focuses on practical RFP evaluation criteria, operational red flags, and due diligence questions sponsors should use when assessing oncology CRO partners.
Key Challenges in Oncology Trials and What to Expect from Your Oncology CRO
Oncology trials come with distinctive challenges that affect trial execution. Sponsors should recognize these upfront, as they inform what to seek in a CRO partner. Key challenges include:
Challenge Area | Why It Matters in Oncology Trials | What to Look for in an Oncology CRO |
Narrow Patient Populations & Enrollment Hurdles | Oncology trials target specific subgroups by tumor type, stage, or biomarker. Only ~5–6% of adult cancer patients enroll in trials. Patients may be dispersed, and multiple trials often compete for the same populations. | Look for CROs with experience in rare and hard-to-reach populations, strong site relationships, and creative recruitment tactics like referral networks and concierge services. |
Biomarker Requirements & Complex Protocols | Many studies require central lab testing, complex assays, and adaptive designs like basket or umbrella trials. These increase site and patient burden, risk protocol deviations, and demand real-time data coordination. | Choose a CRO with deep operational expertise in biomarker logistics, tissue handling, and adaptive trial execution. They should have strong data management and site support processes. |
Evolving Standards and Frequent Changes | Oncology trials often face mid-study amendments due to new therapies, regulatory shifts, or emerging scientific insights. This requires fast protocol updates and IRB re-approvals across regions. | A capable oncology CRO must be nimble, with proven processes for handling protocol amendments and deep knowledge of global regulatory pathways. Statistical fluency is a plus. |
These challenges, scarce patients, biomarker complexity, adaptive designs, and more, underscore why choosing a CRO with genuine oncology expertise is so important. A qualified oncology partner will have strategies to mitigate enrollment barriers, ensure biomarker and data management excellence, and adapt to change so your trial stays on track.
Oncology CRO Evaluation Criteria Sponsors Should Prioritize
Not all CROs are built for oncology. Glossy brochures and big names don’t guarantee performance. If you’re a sponsor evaluating oncology clinical patners, here are seven practical things to focus on — the kind that actually affect timelines, quality, and outcomes.
- Real Oncology Experience
Ask how many oncology trials they’ve run recently. In your indication? Phase I? Biomarker-based? Don’t just accept “yes, we do oncology.” Look for depth — from adaptive trial experience to managing rare cancers — and proof they’ve delivered. Ask about publications, submissions, and regulatory wins.
- Smart Data and Tech Capabilities
Oncology trials create a ton of complex data: imaging, biomarkers, adverse events. You want a CRO that uses reliable EDC platforms, real-time dashboards, and tools like ePRO and remote monitoring. They should integrate lab and genomic data smoothly — and keep it all secure and compliant.
- Site Networks and Global Reach
Enrollment is hard in oncology. The right CRO already knows which sites enroll, how to activate them fast, and how to handle global regulatory differences. Ask for track records — how fast did they enroll 50 patients in a similar study? Do they partner with advocacy groups or referral networks?
- Patient-Centric Thinking
This isn’t about buzzwords — it’s about real actions. Can patients do visits from home? Will the CRO offer flexible scheduling or travel help? Do they think about diversity, burden, and keeping people in the study? Trials only work if patients can stick with them.
- Quality and Compliance
Oncology trials come under serious regulatory scrutiny. Ask if the CRO has passed FDA or EMA inspections. How do they handle safety reports, SAEs, and protocol changes? Their team should be trained specifically in oncology and up to date with evolving regulations (like EU CTR and CTIS).
- Project Execution and Responsiveness
Who will run your trial day to day? Ask for names. You need experienced oncology project managers, not generalists. Ask how they escalate issues, how often they update you, and how they handle surprises — like slow sites or protocol amendments. Execution matters more than promises.
- Flexibility and Fit
Lastly, can they adapt to you? Rigid processes or surprise change orders can derail collaboration fast. Look for a CRO that offers flexible service models and clear change management. You want a team that’s collaborative, not transactional — especially if you’re a smaller sponsor.
Pro tip: Any CRO can say “we’re experienced” or “patient-focused.” Your job is to ask questions that reveal what’s behind the buzzwords. In the next section, we’ll cover exactly which RFP questions help separate talk from track record.
Actionable RFP Questions for Oncology CRO Vendor Assessment
A strong RFP helps you look past sales decks and uncover how a CRO actually works. Below are practical questions that reveal a CRO’s real-world oncology capabilities, and how well they’ll execute your study.
What to Ask | Why It Matters |
“What’s your experience in our cancer type and trial phase?” | Forces the CRO to go beyond general claims and cite relevant case studies or metrics. Ask for outcomes, not just participation. |
“Who will be on our actual project team?” | Avoid the bait-and-switch. Insist on knowing who’s assigned and their oncology background. Ask how team continuity is ensured. |
“How would you approach recruitment and site selection for our study?” | A strong oncology CRO should offer a specific plan based on networks, data, and referral strategies — especially for hard-to-enroll populations. |
“How do you manage protocol amendments or scope changes?” | Oncology trials often shift mid-stream. Ask how fast they implement changes across systems, sites, and budgets. |
“How do you handle oncology-specific data and endpoints?” | Tumor response, imaging, biomarkers — it’s complex. Ask about their data tools, dashboards, and how they track real-time insights. |
“What patient-centric approaches do you offer?” | Look for specific steps: home visits, telehealth, travel support, eConsent, or retention strategies. Don’t settle for buzzwords. |
“How will your team communicate with ours?” | Ask about cadence, tools, escalation process, and how they tailor collaboration to companies of your size and structure. |
“What sets your oncology execution apart from others?” | Give them a chance to show innovation. Look for unique infrastructure, partnerships, or differentiators that go beyond “experience.” |
“Can you share references or recent oncology performance metrics?” | If possible, speak with past clients — or ask for anonymized KPIs (e.g. enrollment speed, protocol adherence, on-time delivery rates). |
Tip: Don’t just evaluate what they say, watch how they respond. A partner with strong oncology execution will be transparent, thoughtful, and responsive in every conversation.
Questions Sponsors Should Ask During Bid Defense
Bid defense meetings often reveal more about operational quality than written proposals.
Sponsors should consider asking:
- What operational risks concern you most in this protocol?
- Which assumptions drive your enrollment forecast?
- How would you respond if enrollment falls behind by 30%?
- What percentage of the proposed team is dedicated full-time to oncology?
- How do you escalate site performance issues?
- What lessons have you learned from failed oncology studies?
- How quickly can you operationalize major amendments across regions?
- Which metrics would trigger an enrollment rescue plan?
The goal is to understand how the CRO thinks operationally under pressure, not simply how well it presents capabilities.
Common Pitfalls in Selecting an Oncology CRO (and How to Avoid Them)
Even experienced sponsors make mistakes when selecting a clinical operations partner. Here are five common ones — and how to steer clear of them.
- Sticking with your usual CRO out of habit
Just because a CRO worked for a past trialdoesn’t mean they’re the right fit for your oncology study. Every program is different.
Avoid it: Always do a market check or short list for new trials. Don’t skip due diligence. - Choosing a big-name CRO just for the brand
Large CROs offer scale, but smaller sponsors often get lower priority. You may not get the team you werepitched.
Avoid it: Ask to meet the actual team. Include named resources in your contract. Consider mid-sized CROs that treat your trial as a priority. - Overweighting oncology experience over execution
Knowing yourindication doesn’t guarantee good delivery. Some CROs struggle with basics like timelines, communication, and data quality.
Avoid it: Look at both experience and past results. Ask for examples of how they handled real challenges — not just their disease knowledge. - Picking the lowest bid
Cheap bids often miss hidden costs. In oncology, complexity meanschange orders can pile up fast.
Avoid it: Compare total cost, not just initial price. Ask about their scope change process and how they’ve handled budget shifts in past trials. - Falling for the “A-team” bait-and-switch
You meet great people during the pitch — then a different team shows up after contract signature.
Avoid it: Lock in named team members contractually. Ask for references that speak to team consistency, not just CRO reputation.
By being aware of these pitfalls, you can proactively address them during selection and contracting. The overarching theme is due diligence: verify claims, trust but verify the team, and don’t rush into a decision based on comfort, price, or a slick presentation alone. Oncology trials are too important to risk on a mismatched partnership.
Choosing the Right Oncology CRO: What Really Matters
Selecting a clinical operations partneris not simply about finding a vendor with oncology experience. Sponsors should evaluate operational execution, enrollment strategy, biomarker infrastructure, regulatory adaptability, governance quality, and the overall strength of the oncology CRO services being offered.
The most successful oncology partnerships are built on transparency, operational realism, flexibility, and proactive communication throughout the study lifecycle.
Sponsors evaluating oncology CRO partners and oncology CRO services should look beyond slide decks and broad capability claims. In complex oncology trials, execution quality ultimately determines whether timelines stay on track, enrollment goals are achieved, and studies reach successful completion.
Cromos Pharma supports oncology programs across phases and indications with flexible operational models, hands-on project oversight, and experience managing complex global oncology studies across the US, Europe, Central Asia, and Türkiye.
